{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:35:39Z","timestamp":1793147739590,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009447","name":"Leukemia and Lymphoma Society of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009447","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000030","name":"Institute of Genetics","doi-asserted-by":"publisher","award":["FDN143312"],"award-info":[{"award-number":["FDN143312"]}],"id":[{"id":"10.13039\/501100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.isci.2025.114216","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T07:53:12Z","timestamp":1764057192000},"page":"114216","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["High-content imaging of primary chronic lymphocytic leukemia cells predicts patient cohorts with distinct cellular drug responses"],"prefix":"10.1016","volume":"28","author":[{"given":"Mark X.","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glauber C.","family":"Brito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarkko","family":"Ylanko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alla","family":"Buzina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Leber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sila","family":"Usta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Tsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Spaner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9266-7157","authenticated-orcid":false,"given":"David W.","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2025.114216_bib1","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1002\/ajh.25595","article-title":"Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment","volume":"94","author":"Hallek","year":"2019","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.isci.2025.114216_bib2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0165-4608(96)00246-4","article-title":"Genetic abnormalities in chronic lymphocytic leukemia and their clinical and prognostic implications","volume":"94","author":"Dierlamm","year":"1997","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.isci.2025.114216_bib3","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature10113","article-title":"Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia","volume":"475","author":"Puente","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.isci.2025.114216_bib4","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nature15395","article-title":"Mutations driving CLL and their evolution in progression and relapse","volume":"526","author":"Landau","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.isci.2025.114216_bib5","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","article-title":"Clinical Staging of Chronic Lymphocytic Leukemia","volume":"46","author":"Rai","year":"1975","journal-title":"Blood"},{"key":"10.1016\/j.isci.2025.114216_bib6","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","article-title":"An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data","volume":"17","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.isci.2025.114216_bib7","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1093\/jnci\/91.10.861","article-title":"Chemotherapeutic Options in Chronic Lymphocytic Leukemia: a Meta-analysis of the Randomized Trials. CLL Trialists' Collaborative Group","volume":"91","year":"1999","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.isci.2025.114216_bib8","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1182\/blood-2016-05-716977","article-title":"Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience","volume":"128","author":"Mato","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.isci.2025.114216_bib9","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1182\/blood-2015-12-687814","article-title":"High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells","volume":"128","author":"Oppermann","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.isci.2025.114216_bib10","doi-asserted-by":"crossref","first-page":"642","DOI":"10.3390\/cancers12030642","article-title":"Precision Medicine Management of Chronic Lymphocytic Leukemia","volume":"12","author":"Moia","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.isci.2025.114216_bib11","doi-asserted-by":"crossref","first-page":"5877","DOI":"10.1182\/bloodadvances.2022008207","article-title":"Targeting conditioned media dependencies and FLT-3 in chronic lymphocytic leukemia","volume":"7","author":"Parvin","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.isci.2025.114216_bib12","article-title":"Live cell painting: New nontoxic dye to probe cell physiology in high content screening","volume":"29","author":"Cottet","year":"2023","journal-title":"SLAS Discov."},{"key":"10.1016\/j.isci.2025.114216_bib13","doi-asserted-by":"crossref","first-page":"72608","DOI":"10.18632\/oncotarget.11618","article-title":"Janus and PI3-kinases mediate glucocorticoid resistance in activated chronic leukemia cells","volume":"7","author":"Oppermann","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.isci.2025.114216_bib14","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.4049\/jimmunol.176.6.3830","article-title":"Sensitization of IL-2 Signaling through TLR-7 Enhances B Lymphoma Cell Immunogenicity","volume":"176","author":"Tomic","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.isci.2025.114216_bib15","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/sj.leu.2404061","article-title":"Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells","volume":"20","author":"Spaner","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.isci.2025.114216_bib16","doi-asserted-by":"crossref","DOI":"10.15252\/msb.202110855","article-title":"Drug-microenvironment perturbations reveal resistance mechanisms and prognostic subgroups in CLL","volume":"18","author":"Bruch","year":"2022","journal-title":"Mol. Syst. Biol."},{"key":"10.1016\/j.isci.2025.114216_bib17","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1182\/blood-2015-11-682906","article-title":"IL-4 enhances expression and function of surface IgM in CLL cells","volume":"127","author":"Aguilar-Hernandez","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.isci.2025.114216_bib18","author":"Byrne"},{"key":"10.1016\/j.isci.2025.114216_bib19","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1002\/ajh.24808","article-title":"IGHV mutational status testing in chronic lymphocytic leukemia","volume":"92","author":"Crombie","year":"2017","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.isci.2025.114216_bib20","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1182\/blood-2016-01-683128","article-title":"Phenotype and immune function of lymph node and peripheral blood CLL cells are linked to transendothelial migration","volume":"128","author":"Pasikowska","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.isci.2025.114216_bib21","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1182\/blood-2015-02-628669","article-title":"CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL","volume":"126","author":"Hagner","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.isci.2025.114216_bib22","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2015-07-567958","article-title":"The novel mechanism of lenalidomide activity","volume":"126","author":"Fink","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.isci.2025.114216_bib23","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1182\/blood-2015-07-660506","article-title":"Gene expression\u2013based discovery of atovaquone as a STAT3 inhibitor and anticancer agent","volume":"128","author":"Xiang","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.isci.2025.114216_bib24","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","article-title":"Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms","volume":"115","author":"Quint\u00e1s-Cardama","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.isci.2025.114216_bib25","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jphs.2016.12.001","article-title":"A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model","volume":"133","author":"Ito","year":"2017","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.isci.2025.114216_bib26","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1158\/1078-0432.CCR-16-1662","article-title":"The Dual Syk\/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia","volume":"23","author":"Blunt","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2025.114216_bib27","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1038\/bcj.2013.6","article-title":"Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F","volume":"3","author":"Ma","year":"2013","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.isci.2025.114216_bib28","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1038\/s41588-022-01211-y","article-title":"Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features","volume":"54","author":"Robbe","year":"2022","journal-title":"Nat. Genet."},{"key":"10.1016\/j.isci.2025.114216_bib29","doi-asserted-by":"crossref","first-page":"6226","DOI":"10.1038\/s41467-022-33385-8","article-title":"Proteogenomics refines the molecular classification of chronic lymphocytic leukemia","volume":"13","author":"Herbst","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2025.114216_bib30","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1038\/nprot.2016.105","article-title":"Cell Painting, a high-content image-based assay for morphological profiling using multiplexed fluorescent dyes","volume":"11","author":"Bray","year":"2016","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.isci.2025.114216_bib31","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1182\/blood-2002-06-1801","article-title":"The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression","volume":"101","author":"Ghia","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.isci.2025.114216_bib32","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1615\/CritRevImmunol.v35.i5.50","article-title":"Role of CD38 Expression in Diagnosis and Pathogenesis of Chronic Lymphocytic Leukemia and Its Potential as Therapeutic Target","volume":"35","author":"Burgler","year":"2015","journal-title":"Crit. Rev. Immunol."},{"key":"10.1016\/j.isci.2025.114216_bib33","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/ijlh.12695","article-title":"CD11c expression in chronic lymphocytic leukemia revisited, related with complications and survival","volume":"39","author":"Umit","year":"2017","journal-title":"Int. J. Lab. Hematol."},{"key":"10.1016\/j.isci.2025.114216_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1043694","article-title":"Paradoxical activation of chronic lymphocytic leukemia cells by ruxolitinib in vitro and in vivo","volume":"13","author":"Spaner","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.isci.2025.114216_bib35","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.3324\/haematol.2015.135418","article-title":"Activity of the Janus kinase inhibitor ruxolitinib in chronic lymphocytic leukemia: results of a phase II trial","volume":"101","author":"Spaner","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.isci.2025.114216_bib36","doi-asserted-by":"crossref","first-page":"8789","DOI":"10.1002\/cam4.4378","article-title":"Janus kinases restrain chronic lymphocytic leukemia cells in patients on ibrutinib: Results of a phase II trial","volume":"10","author":"Spaner","year":"2021","journal-title":"Cancer Med."},{"key":"10.1016\/j.isci.2025.114216_bib37","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/cam4.2042","article-title":"Persistent janus kinase-signaling in chronic lymphocytic leukemia patients on ibrutinib: Results of a phase I trial","volume":"8","author":"Spaner","year":"2019","journal-title":"Cancer Med."},{"key":"10.1016\/j.isci.2025.114216_bib38","first-page":"2579","article-title":"Visualizing High-Dimensional Data Using t-SNE","author":"van der Maaten","year":"2008","journal-title":"J. Mach. Learn. Res."},{"key":"10.1016\/j.isci.2025.114216_bib39","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.201904090","article-title":"A reference library for assigning protein subcellular localizations by image-based machine learning","volume":"219","author":"Schormann","year":"2020","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.isci.2025.114216_bib40","series-title":"Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability","first-page":"281","article-title":"Some methods for classification and analysis of multivariate observations","author":"MacQueen","year":"1967"},{"key":"10.1016\/j.isci.2025.114216_bib41","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1126\/science.1136800","article-title":"Clustering by Passing Messages Between Data Points","volume":"315","author":"Frey","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.isci.2025.114216_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1008630","article-title":"Rapid 3D phenotypic analysis of neurons and organoids using data-driven cell segmentation-free machine learning","volume":"17","author":"Mergenthaler","year":"2021","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.isci.2025.114216_bib43","article-title":"XGBoost: A Scalable Tree Boosting System","author":"Chen","year":"2016","journal-title":"arXiv"}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004225024770?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004225024770?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T02:03:01Z","timestamp":1783476181000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004225024770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":43,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2589004225024770"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2025.114216","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-content imaging of primary chronic lymphocytic leukemia cells predicts patient cohorts with distinct cellular drug responses","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2025.114216","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"114216"}}